Abstract. Circulating anti-islet autoantibodies in sera are used as a predictive marker for type 1 diabetes (T1D). We here report two Japanese patients with autoimmune thyroid disease complicated with T1D in whom the time course of anti-islet autoantibodies were observed before the clinical onset of diabetes. Case 1: A woman who had developed Graves' disease at age 25 was diagnosed with type 2 diabetes at age 31; six months later, insulin therapy was started. At age 36 she was diagnosed with T1D due to glutamic acid decarboxylase 65 autoantibodies (GAD65Ab)-positive status and decreased C-peptide levels. With stored sera we retrospectively followed her anti-islet autoantibodies. GAD65Ab, zinc transporter 8 autoantibodies (ZnT8Ab) and insulin autoantibodies (IAA) were found to be positive at age 25. IAA soon turned negative, but GAD65Ab and ZnT8Ab remained positive with high levels. Insulinoma-associated antigen-2 autoantibodies (IA-2Ab) emerged 2 years before the initiation of insulin therapy. She has T1D-susceptible HLA-DRB1-DQB1 haplotypes, *0405-*0401/*0802-*0302. Case 2: A 49-year-old woman with hypothyroidism due to 19 years' history of atrophic thyroiditis noticed marked thirst, polyuria and weight loss. On admission she was diagnosed as T1D due to GAD65Ab-positive findings and poor C-peptide response to i.v. glucagon. Retrospective serology revealed the emergence of GAD65Ab and IAA just after the clinical onset. IA-2Ab and ZnT8Ab never developed. She has T1D-susceptible and -resistant HLA-DRB1-DQB1 haplotypes, *0901-*0303/*1502-*0601. The autoantibody profile and the mode of diabetes onset in the two cases were remarkably different. These cases imply that anti-islet autoantibodies do not always precede the onset of T1D.
Autoimmune type 1 diabetes (T1D) is a T cellmediated, organ-specific immune disease inducing insulin-deficient state as a result of β cell destruction [1] . Since discovery of islet cytoplasmic autoantibodies (ICA) in the sera from patients with T1D in 1974, a number of anti-islet autoantibodies have been identified [2] . Currently, glutamic acid decarboxylase 65 autoantibodies (GAD65Ab), insulin autoantibodies (IAA) and Insulinoma-associated antigen-2 autoantibodies (IA-2Ab) are used for clinical diagnosis and prediction of autoimmune T1D. Recently, zinc transporter 8 (ZnT8) was identified as a novel autoantigen Emergence of anti-islet autoantibodies in Japanese patients with type 1 diabetes Ichiro Horie 1) , Eiji Kawasaki 2) , Aya Shimomura 1) , Tsuyoshi Satoh 1) , Ikuko Ueki 1) , Hironaga Kuwahara 1) , Takao Ando 1) , Norio Abiru 1) , Toshiro Usa 1) and Katsumi Eguchi 1), 2) in T1D [3] . It is considered that autoantibodies reactive to the islet-cell proteins are produced following β cell destruction by the T cell, and consequent antigen presentation in the draining lymph nodes, and therefore the antibodies are not causal for development of T1D. Emergence of anti-islet autoantibodies in a patient's sera is considered an indicator of on-going β cell destruction by T cell, and a long prodromal phase before the clinical diabetes onset has been recognized in Caucasian patients. However, presence of anti-islet autoantibodies in Japanese patients with T1D before clinical onset of diabetes has never been reported. We here report two Japanese patients with autoimmune thyroid disease (AITD) subsequently developed autoimmune T1D (autoimmune polyglandular syndrome type 3; APS 3). Emergence of anti-islet autoantibodies before or at onset of clinical diabetes was confirmed using stored sera from the patients. cise management, her insulin requirement increased to over 30 units per day in 2005. When her HbA1c level worsened over 10% in July, 2006, she was admitted to our hospital.
On physical examination, she was non-obese (height 165.7 cm, weight 59.2 kg and body mass index (BMI) 21.6 kg/m 2 ), well nourished and in no distress. The significant findings were Graefe's sign, which is a sign of Graves' ophthalmopathy and a diffuse goiter. No diabetic retinopathy or neuropathy was found.
The laboratory findings on admission are summarized in the table. Abnormal findings included hyperglycemia and elevated HbA1c level (9.9 %). The serum level of thyroid hormone was normal, due to her 10 mg/day oral methimazole regimen. The fasting serum C-peptide level was low (0.33 ng/mL) and urinary C-peptide excretion was extraordinarily low, at 7.3 µg/ day. Furthermore, the peak serum C-peptide after 1mg i.v. glucagon was 0.67 ng/mL, and she was recognized as being in an insulin-deficient state. Together with the positive results of GAD65Ab (732.8 U/mL) and ZnT8Ab (0.075 index), she was diagnosed as having methods We retrospectively examined sera from two Japanese patients with AITD complicated T1D. Both patients had been treated with AITD at our hospital for more than 7 years before clinical onset of T1D. We measured anti-islet autoantibodies in their stored samples.
GAD65Ab (normal range; <1.4 U/mL), IA-2Ab (normal range; <0.4 U/mL), anti-thyroglobulin antibody (TgAb, normal range; <0.3 U/mL) and anti-thyorid peroxidase antibody (TPOAb, normal range; <0.3 U/mL) were measured by the commercially available RIA kit (Cosmic Corporation, Tokyo, Japan). IAA (normal range; <125 nU/mL) and thyroid stimulating antibody (TSAb, normal range; <180 %) were measured by Yamasa Corporation's RIA kit (Chiba, Japan). TSH receptor antibody (TRAb, normal range; <1.0 IU/L) were measured by Yamasa Corporation's RRA kit. ZnT8Ab (normal range; index < 0.007) were measured by radioligand binding assay as previously described [4] . C-peptide (CPR) levels were measured by the commercially available ECLIA kit (Roche Diagnostics K.K., Basel, Switzerland).
Case reports

Case 1
Case 1 was a 36-year-old woman who had been diagnosed in 1995 at our hospital with Graves' disease, when she was 25 years of age. She was maintained under good control in a euthyroid state by an oral antithyroid drug. One year later, in 1996, she was diagnosed with gestational diabetes mellitus (GDM) and maintained good glycemic control through her pregnancy with diet therapy. After delivery, her glucose tolerance recovered to normal in the 75g oral glucose tolerance test (OGTT) and she maintained good glycemic control. In 2000, during her second pregnancy at age 30, she was diagnosed again with GDM and was prescribed 8 units per day NPH insulin at the maximum. In May, 2001, in the postpartum period, her glucose tolerance recovered to normal in the 75g OGTT. However, several months after delivery her HbA1c levels gradually became elevated (from 5.0 % to 6.3 %) and she was diagnosed with diabetes by the 75g OGTT in September, 2001. When the value reached 7.6 % in February, 2002, insulin therapy was started (6 units per day of premixed insulin). Even under insulin therapy and improved diet and exerHormonal and immunological analysis Case 1 is taking 10 mg/day methimazole, and case 2 is taking 50 µg/day levothyroxine.
into the insulin-dependent state. IAA was also positive (131.0 nU/mL) in 1996, but soon became negative. The fact that it rose again in 2002 after insulin therapy indicates that the therapy induced anti-insulin antibodies. ZnT8Ab was also positive (0.013 index) in 1996, reaching a peak level just before the emergence of IA-2Ab. Her ZnT8Ab reacted with both ZnT8 aa325 variant constructs bearing 325Trp and 325Arg [4] .
Case 2
Case 2 was a 49-year-old Japanese woman who was operated on for tetralogy of Fallot at the age of 13 years old, diagnosed with Graves' disease in 1988 at autoimmune T1D. She had T1D-susceptible HLA-DRB1-DQB1 haplotypes, *0405-*0401 and *0802-*0302. She had no other autoimmune diseases.
After admission her diabetic control was improved by intensive insulin therapy, comprised of 20 units per day of insulin aspart and 14 units/day of NPH insulin.
As shown in Fig.1 , we measured anti-islet autoantibodies using samples obtained over the previous 10 years. GAD65Ab was found to have been positive (386.1 U/mL) in 1996; the GAD65Ab levels were elevated up to 2076.0 U/mL just before she became insulin dependent, and afterwards fell gradually. On the other hand, IA-2Ab became positive (4 U/mL) just before the second pregnancy, 2 years after which she fell emergence of anti-islet autoantibodies.
Discussion
It is thought that the anti-islet autoantibodies in patients with T1D do not induce the destruction of the pancreatic islet β cells but are a kind of marker produced by the autoantigens that are leaked and presented in the lymphnodes as a result of β cell destruction.
Although a number of anti-islet autoantibodies have been identified, only 3 markers are currently used for diagnosis and prediction of T1D: GAD65Ab, IA-2Ab and IAA. Recently ZnT8Ab has been identified as the 4th molecularly characterized anti-islet autoantibody [3] . If at least one of these autoantibodies is detected in a patient's serum at the onset of diabetes, that patient is diagnosed with autoimmune T1D, i.e. type1A diabetes.
We have previously reported that the prevalences of GAD65Ab, IA-2Ab and IAA were 70 %, 62 %, and 48 %, respectively, in new-onset Japanese patients with T1D, and 89 % were positive for at least one of these autoantibodies [5] . Furthermore, it has been also reported that the level of each autoantibody deteriorates gradually with the duration of T1D and reaches levels below the cut-off. Thus, in general, anti-islet autoantibodies are measured after the clinical onset of T1D, especially in the Japanese population, and there are few reports on the sequential expression of anti-islet autoantibodies before clinical onset of diabetes.
However, in Europe and US, where the prevalence of T1D is much higher than in Japan, such studies in the first-degree relatives of T1D patient have been reported. In the DAISY study in the US, which monitored first-degree relatives of T1D patients who had any anti-islet autoantibodies and whose HLA haplotype was DR3 or DR4, it was reported that GAD65Ab or IAA tended to appear earlier, followed by IA-2Ab, during the pre-diabetic period [6] . Furthermore, it has been also reported that the subjects who had two or more of these autoantibodies had a higher risk for developing T1D compared to those with only 1 autoantibody [7] . Therefore, screening for anti-islet autoantibodies in the prediabetic period is extremely important to predict whether they will develop T1D in the future.
Although the prevalences of anti-islet autoantibodies in new-onset patients with T1D are similar between Japanese [5] and Caucasians [3] , it is unknown whether the appearance of autoantibodies before the age 30, and referred to our hospital. She was treated by an oral anti-thyroid drug. As she became hypothyroid without oral anti-thyroid drug one year later, she was diagnosed with atrophic thyroiditis, and we prescribed her levothyroxine (37.5 µg/day; afterwards a dose up to 50 µg/day since 2006). She remained under good control in a euthyroid state.
In November, 2007, at age 49, she noticed severe thirst, polyuria, general fatigue, and weight loss (-11 kg/6 months). On routine follow-up in May, 2008 her plasma glucose level was 751 mg/dL, so she was admitted to our hospital immediately.
On physical examination, she appeared slightly emaciated (height 157 cm, weight 41 kg and BMI 16.6 kg/m 2 ), with an operation scar on the central sternum and a systolic murmur in 2LSB and 4LSB. Goiter was not palpable. No diabetic retinopathy or neuropathy was found.
The laboratory findings on admission are summarized in the table. The results of complete blood counts and biochemistry were normal except for the diabetes-related data. The HbA1c level was 13.3 %, and the fasting serum C-peptide level was crucially low (0.30 ng/mL) in comparison with the fasting plasma glucose level (374 mg/dL). The urinary C-peptide excretion was also very low (16.6 µg/day). Therefore, it was obvious that impairment of her insulin secretion was severe. Secondary diabetes was ruled out, and she was diagnosed with T1D on the basis of her GAD65Ab-positive (10.5 U/mL) status. She also had no other autoimmune diseases.
After admission her diabetic control was improved by intensive insulin therapy of 36 units per day insulin aspart and 8 units per day insulin glargine. The peak serum C-peptide after 1mg i.v. glucagons at the time of improving from glucose toxicity remained low (0.41 ng/mL). She had both T1D-susceptible and -resistant HLA-DRB1-DQB1 haplotypes, *0901-*0303 and *1502-*0601.
As shown in Fig. 2 , we also analyzed sequential expression of anti-islet autoantibodies and serum glucose levels using the earlier samples. With the sera of before January 8th, 2008, none of anti-islet autoantibodies were detected. GAD65Ab and IAA emerged (1.9 U/mL and 151.1 nU/mL) just after the period (that is April 1st 2008) of appearance of the diabetic symptoms, and IA-2Ab and ZnT8Ab were negative throughout the clinical course. However, serum glucose level was already elevated at 8 months before tibodies is similar to that reported in Caucasians [6] . Of note, ZnT8Ab was also positive 7 years before the clinical onset of diabetes, like GAD65Ab and IAA, and the level of ZnT8Ab increased before the emergence of IA-2Ab.
Case 2 was different from case 1 in terms of the appearance and transition of anti-islet autoantibodies. In this T1D case, GAD65Ab and IAA both emerged just after the clinical onset of diabetes, while IA-2Ab and ZnT8Ab remained negative. According to the reports in Caucasian patients, anti-islet autoantibodies are generally detected in sera of T1D patients more than 10 years before their clinical onset. These facts support the hypothesis by Elliott et al. [9] , namely, that in the early stage of T1D, residual β cells keep clinical onset of T1D in Japanese patients also resembles those in Caucasians. Furthermore, it is difficult to perform such studies in the first-degree relatives of patients with T1D in Japan because the incidence of T1D in Japan is much lower than that in Caucasian populations [8] . During the past 20 years, we have experienced 19 patients with AITD (18 with Graves' disease and one with Hashimoto's thyroiditis) who developed T1D later. Among them we were able to observe the appearance of anti-islet autoantibodies before the clinical onset of T1D only in two patients described here.
In case 1, GAD65Ab and IAA were present more than 7 years before the clinical onset of diabetes, and IA-2Ab emerged about 2 years before the patient became insulin dependent. This time course of autoan- glucose tolerance normal even if the autoimmune attack to pancreatic islet β cells begins, and overt diabetes develops when β cell function cannot maintain the normal plasma glucose level after the progression of β cell destruction. Moreover, the in vivo study by Sreenan et al. [10] with non-obese diabetic (NOD) mice, an animal model of human T1D, supports this hypothesis. They recognized that the plasma glucose levels of NOD mice rose after the destruction of more than 70 % of their islet cells by infiltrating lymphocytes.
The time course of anti-islet autoantibodies in case 1 supports these reports. It is possible that most of the pancreatic islet β cells in this case were destroyed in a short period. However, in case 2, it may have been dif-ficult to predict her clinical onset of T1D even if she had done careful follow-up by the attending physician because anti-islet autoantibodies emerged just after the clinical onset of diabetes. Much lower titer of antiislet autoantibodies in case 2 compared to case 1 may reflect her mode of diabetes onset. Although she has one of the resistant HLA haplotypes in the Japanese population, its contribution to her time course of antiislet autoantibodies is unknown.
These results imply that the mode of development of anti-islet autoantibodies before clinical onset of T1D is variable in Japanese patients, and that the onset of T1D is not always preceded by the presence anti-islet autoantibodies.
